Related Experiment Video
Updated: Aug 21, 2026

Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance
Published on: July 28, 2023
14-Day Vonoprazan-Minocycline Dual Therapy Versus Bismuth-Containing Quadruple Therapy for Helicobacter pylori Rescue
Tingting Yang1,2, Ruijuan Xin2, Yanhong Deng2
1The Third Clinical Medical College, Ningxia Medical University, Yinchuan, China.
Background:
Rescue treatment for Helicobacter pylori infection remains challenging in regions with high antibiotic resistance. Although bismuth-containing quadruple therapy is widely recommended as an empirical rescue regimen, its medication burden may impair tolerability and adherence. This trial evaluated the efficacy and safety of 14-day vonoprazan-minocycline dual therapy compared with vonoprazan-based bismuth-containing quadruple therapy as empirical rescue treatment.
Materials And Methods:
This single-center, prospective, open-label, randomized, controlled, noninferiority trial enrolled 186 adults aged 18-70 years with at least one previous H. pylori eradication failure. Patients were randomly assigned (1:1) to receive 14-day vonoprazan-minocycline dual therapy or vonoprazan-, amoxicillin-, minocycline-, and bismuth-containing quadruple therapy. Eradication was assessed by a 13C urea breath test 4 weeks after treatment. ITT, mITT, and PP analyses were performed, with a prespecified noninferiority margin of -10%.
Results:
Eradication rates in the dual therapy and quadruple therapy groups were 89.2% and 91.4% in the ITT analysis (difference, -2.2%; 95% CI, -10.5% to 6.2%; noninferiority p = 0.036), 90.2% and 92.4% in the mITT analysis (difference, -2.2%; 95% CI, -9.7% to 5.3%; noninferiority p = 0.030), and 91.2% and 93.4% in the PP analysis (difference, -2.2%; 95% CI, -9.4% to 5.0%; noninferiority p = 0.024). Noninferiority was demonstrated in the mITT and PP analyses, whereas the ITT result should be interpreted cautiously because the lower 95% CI bound crossed the margin. Adverse events were similar between treatment groups (11.8% vs. 15.1%; χ2 = 0.416; p = 0.519), and adherence was high in both groups (97.8% vs. 97.8%; p = 1.000).
Conclusions:
14-day vonoprazan-minocycline dual therapy achieved eradication rates comparable to those of bismuth-containing quadruple therapy, with acceptable safety and high adherence as rescue treatment for H. pylori infection. This simplified regimen may be considered a potential empirical rescue option when susceptibility testing is not readily available, although the ITT noninferiority result warrants cautious interpretation.
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease II: Pathophysiology
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
